Cargando…
Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
SIMPLE SUMMARY: The cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors palbociclib, ribociclib and abemaciclib have transformed the lives of patients with ER+/HER2− metastatic breast cancer (MBC). Clinical trials have shown that all three CDK4/6 inhibitors improve progression-free survival (PFS), but...
Autores principales: | Tang, Hiu, Yeo, Daniel, De Souza, Karen, Ahmad, Omar, Shafiq, Tahir, Ofor, Okezie, Anand, Anjana, Karim, Syed, Khan, Sarah, Madhusudan, Srinivasan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647609/ https://www.ncbi.nlm.nih.gov/pubmed/37958338 http://dx.doi.org/10.3390/cancers15215164 |
Ejemplares similares
-
Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017) -
ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022) -
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021) -
3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and
Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021) -
Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)